|
We are delighted to announce that for 2012 we are significantly increasing DDI Award levels!
- $25,000 for in vitro studies
- $50,000 for in vivo studies
- $75,000 for Advanced in vivo studies (applications by invitation only)
2012 DDI Award deadlines:
- February 28, 2012
- August 31, 2012
Click here to view full application and RFA.
2011 DDI Awardees
- Cristina Fernadez-Valle, Ph.D., University of Central Florida
Preclinical testing of the mTORC1 inhibitor Rapamycin in NF2 meningioma mouse models
- Jan Friedman, MD, Ph.D., University of British Columbia
Cytokine inhibitors for the treatment of NF1 Vasculopathy
- Xu Wu, Ph.D., Harvard Medical School/ Massachusetts General Hospital
Small Molecule Library of Inhibitors of YAP Nuclear Localization in NF2 Schwannoma, Astrocytoma, Meningioma Cells
- David Largaesapada, Ph.D., University of Minnesota*
Drug combinations for NF1 Plexiform Neurofibroma and MPNST
(Builds on previous in vitro DDI Award)
- David Wiemer, Ph.D., University of Iowa
Advanced DDI Award to optimize Schweinfurthins for NF1 Astrocytoma
(Builds on previous DDI Award)
*Dr. Largaespada’s Award is funded by the Texas Neurofibromatosis Foundation through CTF.
2010 DDI Awardees
- Michel Kalamarides, MD, Ph.D., House Ear Institute
Screening a small molecule drug library on NF2 Schwannoma Cells
- Thomas Look, MD, Dana Farber Cancer Institute
A Zebrafish Chemical Approach to NF1 Pathogenesis
- Morvarid Mohseni, Ph.D., Children’s Hospital Boston
Small molecule screen to identify inhibitors of NF2- mediated Yap1 activation
- Margaret Wallace, Ph.D., University of Florida
ln vivo preclinical trial of PTC124 in human NFl xenografts
- Marco Giovannini, MD, Ph.D., House Ear Institute
Preclinical testing of the covalent pan-ErbB inhibitor CNX-222 in NF2 schwannoma mouse models (Advanced DDI Award)
- Andrea McClatchey, Ph.D., Harvard Medical School/Massachusetts General Hospital
Preclinical testing of covalent pan-ErbB inhibitors in vitro and in vivo models of NF2 (Advanced DDI Award)
- David Largaespada, Ph.D., University of Minnesota
Genetically Guided, Combinatorial, Targeted Therapy for MPNST
- Rajesh Khanna, Ph.D., Indiana University
Screening and validation of peptide‐based disruptors of the neurofibromin and CRMP‐2 interaction as novel therapeutic tools for NF1.
2009 DDI Awardees
- Marco Giovannini, MD, Ph.D., House Ear Institute
Evaluating pan-ErbB inhibitor CNX-222 in NF2 xenografts (with Avila Therapeutics)
- Marianne James, Ph.D., Harvard Medical School/Massachusetts General Hospital
Testing mTOR inhibitors to target NF2 menigioma cell proliferation
- Mark Philips, MD, New York University Langone Medical Center
Icmt inhibitors as candidate therapies for NF1 MPNSTs
- Larry Sherman, Ph.D.
Therapeutic pain modulation in a mouse model of schwannomatosis (with Pfizer and AstraZeneca Pharmaceuticals)
- Margaret Wallace, Ph.D., University of Florida
PTC-299 assessment in NF1 plexiform neurofibromas (with PTC Therapeutics)
- Jonathan Chernoff, Ph.D., Fox Chase Cancer Center
Induced pluripotent stem cell therapy for treatment of NF1 plexiform neurofibroma
- Marco Giovannini, MD., Ph.D., House Ear Institute
Hsp90 inhibitors for NF2 vestibular schwannoma (with NexGenix Pharmaceuticals)
- Joseph Kissil. Ph.D., The Wistar Institute
New chemical entities to inhibit PAK in NF2 vestibular schwannoma
- Andrea McClatchey, Ph.D., Harvard Medical School/Massachusetts General Hospital
panErbB inhibitors as candidate treatments for NF2 associated tumors (with Avila Therapeutics)
2008 DDI Awardees
- Oliver Hanemann, MD, Ph.D., University of Plymouth, United Kingdom
Testing Sorafenib and NVP-BEZ-235 in a human schwannoma in vitro model (two awards)
- Florent Elefteriou, Ph.D., Vanderbilt University Medical Center
Local nanoparticle delivery of Lovastatin to improve NF1 bone healing in Nf1 ob-/- mice
- Joshua Rubin, MD, Ph.D., Washington University School of Medicine
Maximizing Efficacy While Minimizing Toxicity in the Treatment of Nf1 Optic Pathway Glioma: Novel combinatorial therapy with Rolipram and Temozolomide
- Jonathan Chernoff, MD, Ph.D., Fox Chase Cancer Center
Synthetic lethal screen of FDA-approved drugs in NF2
- Bernard Maria, MD, MBA, Medical University of South Carolina
Targeting Hyaluronan-CD44 interaction in MPNSTs
- Bakhos A. Tannous, Ph.D. Harvard Medical School/Massachusetts General Hospital
In vivo screening for NF2 meningioma therapeutics
- Margaret Wallace, Ph.D., University of Florida
Analysis of nonsense-suppressing compounds in NF1
- David Wiemer, Ph.D., University of Iowa
Improving the activity and reducing the toxicity of synthetic schweinfurthins using a mouse model of NF1-associated malignancies
2007 DDI Awardees
- Gary J. Brenner, MD, Ph.D. Harvard Medical School/Massachusetts General Hospital
Screening of EGFR inhibitor/apoptotic drug combination in NF2 schwannoma xenograft mouse model
- Emmanuelle Di Tomaso, Ph.D., Massachusetts General Hospital/Harvard Medical School
Targeting vessels and tumors in NF2 schwannomas
- Cristina Fernandez-Valle, Ph.D. University of Central Florida
Do anti-ErbB2 drugs slow proliferation of MPNSTs in vitro?
- Frances Hannan, Ph.D., New York Medical College
Pharmacological dissection of cognition in a fly NF1 model
- Abraham Jacob, MD, Ohio State University
Preclinical testing of a novel AKT inhibitor OSU-03012 using an NF2 vestibular schwannoma xenograft model
- Susan Lindquist, Ph.D., Whitehead Institute of Technology
Screening for Inhibitors of Heat Shock Transcription Factor 1: a Novel Therapeutic Target in NF1
- Andrea McClatchey, Ph.D., Harvard Medical School/Massachusetts General Hospital
Screening of EGFR inhibitors in a transgenic NF2 tumorigenesis model
- David Wiemer, Ph.D., University of Iowa
Screening the natural product schweinfurthin as a candidate therapeutic for NF1-associated malignancies using xenograft and transgenic mouse models
2006 DDI Awardees
- Karen Cichowski, Ph.D., Harvard Medical School/Brigham & Women’s Hospital
Assessing the effects of Rapamycin on a mouse of MPNST development
- Abhijit Guha, MD, FRCSC, FACS, University of Toronto, Canada
Rapamycin as sole or adjuvant therapy for human NF1-associated MPNST
- Stefan Mundlos MD, Ph.D., Max Planck Institute, Germany
Lovastatin treatment of bone injury in the NF1flox; Prx1Cre mice
- Nancy Ratner, Ph.D., Cincinnati Children’s Hospital Medical Center
Chemical Screen for NF-1 Specific Compounds
- Joshua Rubin MD, Ph.D., Washington University School of Medicine
Preclinical evaluation of phosphodiesterase inhibition in a mouse model of NF1 optic pathway glioma
|
For Scientists 
